Factors Associated With Clearance of BK Polyomavirus Viremia at 4 Months After Hematopoietic Cell Transplant
| . | Did Not Clear Viremia at Month 4 . | Cleared Viremia at Month 4 . | P a . |
|---|---|---|---|
| n = 31b | n = 21b | ||
| Peak viremia ≥10 000 copies/mL in the first 3 months after transplant | 21 (67.7%) | 3 (14.3%) | <.001 |
| Month 3 BK polyomavirus IgG | n = 31 | n = 20 | .49 |
| 1:2560 | 2 (6.5%) | 2 (10.0%) | |
| 1:10 240 | 17 (54.8%) | 7 (35.0%) | |
| 1:40 960 | 10 (32.3%) | 8 (40.0%) | |
| 1:163 840 | 2 (6.5%) | 3 (15.0%) | |
| Month 3 absolute lymphocyte count, cells/µL | 646 (260–880) | 780 (500–970) | .15 |
| Received cidofovir in first 3 months after transplant | 17 (54.8%) | 3 (14.3%) | .004 |
| Month 3 ELISPOT spots above negative control | n = 25 | n = 18 | |
| Number of spots | 1.3 (0–8.4) | 20.1 (2.9–48.5) | .007 |
| >5 spots | 9 (36.0%) | 12 (66.7%) | .05 |
| >10 spots | 6 (24.0%) | 11 (61.1%) | .01 |
| . | Did Not Clear Viremia at Month 4 . | Cleared Viremia at Month 4 . | P a . |
|---|---|---|---|
| n = 31b | n = 21b | ||
| Peak viremia ≥10 000 copies/mL in the first 3 months after transplant | 21 (67.7%) | 3 (14.3%) | <.001 |
| Month 3 BK polyomavirus IgG | n = 31 | n = 20 | .49 |
| 1:2560 | 2 (6.5%) | 2 (10.0%) | |
| 1:10 240 | 17 (54.8%) | 7 (35.0%) | |
| 1:40 960 | 10 (32.3%) | 8 (40.0%) | |
| 1:163 840 | 2 (6.5%) | 3 (15.0%) | |
| Month 3 absolute lymphocyte count, cells/µL | 646 (260–880) | 780 (500–970) | .15 |
| Received cidofovir in first 3 months after transplant | 17 (54.8%) | 3 (14.3%) | .004 |
| Month 3 ELISPOT spots above negative control | n = 25 | n = 18 | |
| Number of spots | 1.3 (0–8.4) | 20.1 (2.9–48.5) | .007 |
| >5 spots | 9 (36.0%) | 12 (66.7%) | .05 |
| >10 spots | 6 (24.0%) | 11 (61.1%) | .01 |
Data are shown as a median (interquartile range) or n (%).
Abbreviation: ELISPOT, enzyme-linked immune absorbent spot.
a P value by Wilcoxon rank sum, 2-sample t test, Chi-square, or Fisher’s exact test, as appropriate.
bThe included participants had detectable viremia on ≥2 samples in the first 3 months after transplant and had a Month 4 blood sample to assess for viral clearance. Clearance was defined as having undetectable viremia at Month 4.
Factors Associated With Clearance of BK Polyomavirus Viremia at 4 Months After Hematopoietic Cell Transplant
| . | Did Not Clear Viremia at Month 4 . | Cleared Viremia at Month 4 . | P a . |
|---|---|---|---|
| n = 31b | n = 21b | ||
| Peak viremia ≥10 000 copies/mL in the first 3 months after transplant | 21 (67.7%) | 3 (14.3%) | <.001 |
| Month 3 BK polyomavirus IgG | n = 31 | n = 20 | .49 |
| 1:2560 | 2 (6.5%) | 2 (10.0%) | |
| 1:10 240 | 17 (54.8%) | 7 (35.0%) | |
| 1:40 960 | 10 (32.3%) | 8 (40.0%) | |
| 1:163 840 | 2 (6.5%) | 3 (15.0%) | |
| Month 3 absolute lymphocyte count, cells/µL | 646 (260–880) | 780 (500–970) | .15 |
| Received cidofovir in first 3 months after transplant | 17 (54.8%) | 3 (14.3%) | .004 |
| Month 3 ELISPOT spots above negative control | n = 25 | n = 18 | |
| Number of spots | 1.3 (0–8.4) | 20.1 (2.9–48.5) | .007 |
| >5 spots | 9 (36.0%) | 12 (66.7%) | .05 |
| >10 spots | 6 (24.0%) | 11 (61.1%) | .01 |
| . | Did Not Clear Viremia at Month 4 . | Cleared Viremia at Month 4 . | P a . |
|---|---|---|---|
| n = 31b | n = 21b | ||
| Peak viremia ≥10 000 copies/mL in the first 3 months after transplant | 21 (67.7%) | 3 (14.3%) | <.001 |
| Month 3 BK polyomavirus IgG | n = 31 | n = 20 | .49 |
| 1:2560 | 2 (6.5%) | 2 (10.0%) | |
| 1:10 240 | 17 (54.8%) | 7 (35.0%) | |
| 1:40 960 | 10 (32.3%) | 8 (40.0%) | |
| 1:163 840 | 2 (6.5%) | 3 (15.0%) | |
| Month 3 absolute lymphocyte count, cells/µL | 646 (260–880) | 780 (500–970) | .15 |
| Received cidofovir in first 3 months after transplant | 17 (54.8%) | 3 (14.3%) | .004 |
| Month 3 ELISPOT spots above negative control | n = 25 | n = 18 | |
| Number of spots | 1.3 (0–8.4) | 20.1 (2.9–48.5) | .007 |
| >5 spots | 9 (36.0%) | 12 (66.7%) | .05 |
| >10 spots | 6 (24.0%) | 11 (61.1%) | .01 |
Data are shown as a median (interquartile range) or n (%).
Abbreviation: ELISPOT, enzyme-linked immune absorbent spot.
a P value by Wilcoxon rank sum, 2-sample t test, Chi-square, or Fisher’s exact test, as appropriate.
bThe included participants had detectable viremia on ≥2 samples in the first 3 months after transplant and had a Month 4 blood sample to assess for viral clearance. Clearance was defined as having undetectable viremia at Month 4.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
